NEWS & EVENTS
August 17, 2022
A New Cooperation between EZH2 and p38 Proteins Enhances Metastasis in Triple Negative Breast Cancer
The Celina Kleer lab at the University of Michigan Department of Pathology and Rogel Cancer Center has found a new mechanism that fuels metastasis in triple negative breast cancers. In their new study they show that EZH2, a master regulator of cell type identity, known to function through methylation of histones, has a new, unexpected function in aggressive breast cancers. By adding methyl groups to the p38 protein, EZH2 enhances the ability of breast cancer cells to spread to other tissue throughout the body, a process known as metastasis.
July 25, 2022
On Thursday, July 15, Scott Marquette, Associate Chief Operating Officer from Michigan Medicine, visited the Clinical Microbiology laboratory at the Department of Pathology. The purpose of the visit was to learn more about the Visual Inventory Management pilot, a new initiative that is intended to help lab staff better organize their tools, resources and assets within the lab setting.
July 11, 2022
The Department of Pathology's Clinical Operations Director Kristina Martin recently received the Scientific-Assembly Laboratory Administration award from the American Society for Clinical Laboratory Science (ASCLS) at the Joint Annual Meeting in Grand Rapids, Michigan last month. The award recognizes outstanding professional achievement of an individual ASCLS member within his or her chosen area of academic, scientific, or vocational interest.
NGS Solid Tumor Panel
Molecular testing of solid tumor neoplasms - particularly advanced-stage cancer. This DNA and RNA based, NGS test targets 50 actionable genes (35 mutations, 19 amplifications, 21 - fusions). Requires <1mm2 of tissue (as little as 100 tumor cells) and a low 3% QNS rate.
NEW TREATMENT OPTION FOR METASTATIC BREAST CANCER
MLabs offers NGS Solid Tumor Panel and Single gene test to detect PIK3CA for FDA approved therapy alpelisib (Piqray®).
Myeloid NGS Panel
This test is intended for the molecular evaluation of myeloid neoplasms including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemias (AML), mastocytosis and myeloid neoplasms with eosinophilia and gene rearrangement.
Erdafitinib (Balversa™) is an FGFR-inhibitor that is FDA-approved for the treatment of metastatic urothelial cancers harboring susceptible mutations or translocations involving FGFR2 or FGFR3.
NR4A3 (9q22-9q31) Rearrangement (FISH)
NR4A3 encodes an orphan nuclear receptor. Rearrangements of NR4A3 occur in more than 80% of extraskeletal myxoid chondrosarcoma (EMC) as well as in salivary acinic cell carcinoma (AciCC), driving tumorigenesis.
TFE3 Rearrangement (FISH)
Detecting rearrangements involving the TFE3 gene region (Xp11.2) via fluorescence in situ hybridization (FISH) to qualitatively assess for the presence of TFE3 translocations that are associated with certain subtypes of renal cell carcinoma. Testing for TFE3 gene rearrangement may aid in the diagnosis and classification of renal tumors.